Clinical Study
Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke
Table 2
Summary of detailed characteristics of subjects with recurrent stroke.
| Number | Sex | Age | Treatment | D-dimer level (μg/mL) on admission | D-dimer level (μg/mL) at the time of recurrence | INR at the time of recurrence | Time to recurrence (months) | Primary cancer type | Adenocarcinoma | Systemic metastasis |
| 1 | Female | 55 | Warfarin | 19.54 | 47.80 | 3.04 | 1.13 | Lung | Yes | Yes | 2 | Male | 72 | Warfarin | 1.91 | 2.96 | 1.48 | 0.80 | Lung | Yes | No | 3 | Female | 59 | Warfarin | 72.40 | 47.20 | 2.60 | 0.83 | CBD | Yes | Yes | 4 | Male | 61 | Warfarin | 60.00 | 39.72 | 2.62 | 0.46 | Colon | Yes | Yes | 5 | Female | 60 | Warfarin | 18.36 | 10.30 | 1.39 | 8.30 | Lung | Yes | Yes | 6 | Female | 51 | Warfarin | 11.74 | 57.93 | 5.51 | 19.63 | Lung | Yes | Yes | 7 | Female | 48 | Warfarin | 4.83 | 0.34 | 3.26 | 1.90 | Lung | Yes | Yes | 8 | Female | 75 | Warfarin | 14.87 | 14.74 | 2.06 | 0.37 | Pancreas | Yes | Yes | 9 | Male | 67 | Enoxaparin | 60.00 | 60.00 | N/A† | 0.43 | CBD‡ | Yes | Yes |
|
|
INR, international normalized ratio; †N/A: not applicable; ‡CBD: common bile duct.
|